Cells
Mechanistic research
- Genomic stability
- Cellular senescence signaling
- Stress resilience
- Healthy inflammatory response
Cellular and biochemical research showing whether relevant aging biology can be affected. Cells are not people.
A new standard for longevity supplements
Most companies sell supplements. NOVOS runs a longevity research program.
Thousands of products call themselves longevity supplements. But an ingredient affecting one molecule or one biomarker does not by itself demonstrate meaningful support for how the body ages.
NOVOS Core was designed as a coordinated system targeting the 12 Hallmarks of Aging, then investigated through mechanistic studies, aged-animal models and human clinical research.
Mechanistic studies. Animal models. Placebo-controlled human research.
Clinical research validated that NOVOS Core provides nutritional support for biological systems predictive of lifespan and healthspan.
NOVOS Core
12 ingredients. 12 Hallmarks of Aging. One coordinated formulation.
8
Years of research
7
Scientists + MDs formulated
7
Whole formulation studies
950+
Ingredient studies
2,000+
MDs & clinicians recommend
15M+
NOVOS servings
Available at
Mayo Clinic Store
Bumrungrad International Hospital
Erewhon
Equinox
Remedy Place
Four Seasons
Sunlife Organics
Member of & selected for
Longevity Biotechnology Association
Healthy Longevity Medicine Society
XPRIZE Top 100 Healthspan Competition
Third-party tested. Retail availability does not imply institutional medical endorsement.
Why Core is different
Aging doesn’t happen in one place.
The supplement industry sells aging as a single switch.
Scroll social media and the story is always the same: your mitochondria are the problem. Or your stem cells. Or DNA damage. Or senescent cells. Take this one collagen powder, this one peptide, this one miracle molecule, and the effects of aging simply disappear.
It is a compelling pitch because it is simple. It is also wrong. Each of these interventions touches one real piece of biology, and leaves the rest of the aging process untouched.
Useful biology?
Yes.
The whole aging process?
Not even close.
Tap a strategy. Only one part of the cell lights up. The rest of aging keeps going without it.
Scientists now agree: aging runs on 12 interconnected drivers.
Over the past decade, longevity researchers have converged on a framework called the 12 Hallmarks of Aging: the core biological processes that drive how fast we age, how long we stay healthy, and ultimately how long we live.
Crucially, the Hallmarks are not independent. Damage to DNA accelerates cellular senescence. Senescent cells drive chronic inflammation. Inflammation disrupts nutrient sensing and mitochondrial function. Every Hallmark pushes on the others, which is why addressing only one can never be enough.
Meaningful longevity support means addressing the system, not a single switch.
DNA accumulates damage over time, and repair systems work less efficiently.
Protective caps at the ends of chromosomes shorten as cells divide.
Chemical marks on DNA shift with age and change which genes are active.
Cells become less able to fold, maintain and recycle proteins correctly.
The cellular recycling system slows down and debris builds up.
Pathways that read energy availability drift away from youthful signaling.
Energy production becomes less efficient and more error prone.
Some cells stop dividing but stay active and signal to neighboring tissue.
Tissue renewal slows because regenerative cell pools decline.
Signals between cells and tissues become noisier with age.
Low grade inflammatory signaling rises across many tissues.
The microbial community in the gut shifts in composition and function.
Core was built around the aging system, not one trendy pathway.
NOVOS Core is the first patent-pending formulation designed to address all 12 Hallmarks of Aging simultaneously: 12 ingredients, selected and dosed so their effects overlap across every hallmark.
Because aging cannot be treated with simple approaches in isolation, and there is no single miracle molecule. There never was.
Tap an ingredient to see which Hallmarks it supports
Studied in senescent-cell biology, with roles that also touch telomere, stem-cell and inflammatory pathways.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
A metabolic intermediate linked to nutrient sensing, epigenetic regulation and genomic maintenance.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Supports methylation and glutathione biology, connecting genomic, epigenetic and stem-cell pathways.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Feeds mitochondrial energy metabolism while supporting DNA repair enzymes and nutrient-sensing balance.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Associated with cell-signaling balance and stress resilience relevant to telomere biology.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Explored in autophagy and proteostasis research, with links to gut and structural biology.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Broad activity across inflammatory signaling, senescence-associated secretion and gut ecology.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
A cofactor for collagen synthesis and for enzymes involved in epigenetic and mitochondrial function.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Extracellular-matrix biology, tissue hydration and inflammatory-response support.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Adaptogenic biology touching mitochondrial function and epigenetic regulation.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Trace-level signaling associated with intercellular communication and senescence pathways.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Part of the citric-acid cycle, connecting energy production with cellular recycling.
H1 Genomic instability
H2 Telomere attrition
H3 Epigenetic alterations
H4 Loss of proteostasis
H5 Disabled macroautophagy
H6 Deregulated nutrient sensing
H7 Mitochondrial dysfunction
H8 Cellular senescence
H9 Stem cell exhaustion
H10 Altered intercellular communication
H11 Chronic inflammation
H12 Dysbiosis
Single-pathway approach
- NAD+ boosters
- Focus primarily on one important area of aging biology.
- Senolytics
- Focus primarily on cellular senescence.
- Collagen
- Focuses primarily on structural support.
- Antioxidants
- Focus primarily on oxidative-stress biology.
Useful tools. None of them is the whole answer.
NOVOS Core
The multi-pathway longevity foundation.
- Designed around all 12 Hallmarks of Aging
- With 12 complementary, overlapping ingredients
- Patent-pending, and backed by whole-formulation research
The formula itself has been studied.
The goal was never to find one magic longevity molecule. It was to build a formulation around the biology of aging itself.
Calling something a “longevity supplement” does not make it one.
A molecule can change.
That tells us biology was affected, but not if it will impact healthspan or lifespan.
A biomarker can change.
That tells us a measurable signal changed, but not whether it will impact healthspan or lifespan.
Someone can feel different.
That tells us about subjective experience, but not whether their aging slowed or health improved.
But longevity is a bigger question.
Cells
Did we impact the processes that cause aging?
Animal models
By impacting those processes, were we able to extend animal lifespan and healthspan?
Human physiology
Were we able to improve organ function in humans that’s associated with healthspan and lifespan?
NOVOS investigates all three.
NOVOS Core is a rigorously studied longevity formula, rare in the dietary supplement market.
LBA
NOVOS is the only dietary supplement company that is a member of the Longevity Biotechnology Association.
The evidence journey
What has actually been studied?
Aged animals
Lifespan and healthspan research
- The complete Core formulation has been evaluated in aged-animal research involving lifespan and functional health, with successful results.
Whole-organism animal research. It can test long-duration outcomes, but it does not establish the same result in humans.
Human biological aging
Preliminary epigenetic research
- NOVOS Core + NOVOS Boost
- Statistically significant reduction in DunedinPACE pace of aging measurement
Humans were studied, but without randomization or a placebo group. Findings are preliminary and cannot establish causation.
Placebo-controlled human clinical research
Functional physiology
- Improvements in: endothelial function
- Arterial flexibility
- Healthy blood pressure support
The complete finished product was tested in humans under randomized, double-blind, placebo-controlled conditions.
The first human system we measured
Why start with cardiovascular aging?
Cardiovascular function is one of the most consequential systems to preserve as we age.
Blood vessels become less flexible. Endothelial function can decline. Blood pressure tends to rise. These changes are part of the physiology of aging, even before disease is present.
And the cardiovascular system does not operate in isolation. It supplies oxygen and nutrients to nearly every tissue in the body, from the brain and muscles to the kidneys, skin and other organs.
That made cardiovascular function a powerful first place to ask a larger question:
Can NOVOS Core’s unique approach of targeting the 12 Hallmarks of Aging measurably support a major physiological system that changes with age?
It changes with age
Vascular function changes over time.
With age, arteries tend to become less flexible and endothelial responsiveness can decline.
Blood pressure also commonly rises across adulthood.
These are measurable changes in physiology, which makes the cardiovascular system highly relevant to healthy-aging research.
The whole body depends on it
Every organ depends on circulation.
The cardiovascular system delivers oxygen, nutrients and hormonal signals, and helps transport metabolic products throughout the body.
Healthy circulation therefore supports much more than the heart. It supports the environment in which cells and organs throughout the body function.
You cannot separate cardiovascular health from whole-body health.
The stakes are high
Cardiovascular disease is the #1 cause of age related decline and death.
Cardiovascular disease remains the leading cause of death worldwide, and risk rises substantially with age.
That makes cardiovascular physiology more than a convenient biomarker.
It is one of the most consequential systems to understand and preserve across the lifespan.
Cardiovascular aging is aging.
One important system within a much broader aging process, and one of the clearest places to measure whether that process is being supported.
Foundational infrastructure
Cardiovascular function is foundational infrastructure for the whole body.
Brain
Requires continuous blood flow, oxygen and nutrient delivery.
Muscle
Depends on circulation for oxygen delivery, nutrients and exercise capacity.
Kidneys
Receive substantial blood flow and help regulate fluid and blood-pressure physiology.
Skin
Circulation supports nutrient and oxygen delivery to tissue.
Liver
Metabolic work depends on a steady supply of blood, oxygen and nutrients.
Whole body
Every tissue sits downstream of circulation. Cardiovascular function is foundational infrastructure for the whole body.
Illustrative of normal circulatory physiology. No organ-specific disease claims are made.
That is why cardiovascular function was the first system we tested in humans.
It changes meaningfully with age.
It affects the health of virtually every organ.
It has enormous consequences for long-term health.
And importantly for a clinical study, it can be measured using validated functional endpoints.
Endothelial function
How well blood vessels respond when increased blood flow is required.
Arterial flexibility
How elastic the large arteries are, critical for cardiovascular health.
Healthy blood pressure
Whether pressure can be improved starting from within a healthy range.
Cardiovascular function was the first major physiological system we measured in humans. It was not the only system NOVOS Core was designed to support.
Core was designed around the broader biology of aging and the 12 Hallmarks of Aging.
The cardiovascular study gave us something especially valuable:
a way to test whether that upstream formulation approach could produce downstream measurable effects on human physiology.
From signals to function
We wanted to measure more than a biomarker.
Many studies show that a molecule or laboratory marker changed. That can be scientifically useful.
But for NOVOS Core, we also wanted to know something more consequential: did an important physiological system actually function differently?
Biological signal
Indirect / molecular measurement
A biological signal changed.
These measurements can tell us that biology has changed. But they do not always tell us whether an organ or physiological system is functioning better.
Useful. Important. But one layer of evidence.
Physiological function
Direct / functional measurement
The system itself functioned differently.
A blood vessel can dilate differently. An artery can transmit a pressure wave differently. Blood pressure can change. These measurements assess how the cardiovascular system actually performs.
That is a much higher bar.
NOVOS Core was not evaluated only by asking whether a molecule moved. We measured whether a major aging-related physiological system functioned differently in humans.
Core was tested at both levels, and the randomized human study focused on functional physiology.
6 months
Randomized
Double blind
Placebo controlled
Adults 40+
Randomized human research
We tested the complete NOVOS Core formula.
6 MONTHS
RANDOMIZED
DOUBLE BLIND
PLACEBO CONTROLLED
ADULTS 40+
In a six-month randomized, double-blind, placebo-controlled human study, NOVOS Core demonstrated beneficial effects over placebo on multiple functional biomarkers used in aging and cardiovascular research.
Human clinical data is the strongest form of validation, and its meaning deepens when multiple independent measures point in the same positive direction.
The complete finished product was tested in humans under randomized, double-blind, placebo-controlled conditions.
Publication status: manuscript under peer review at the time of writing.
The complete finished formula that is available for purchase is what was tested.
Three human results
What the study measured in humans.
Endothelial function
FMD
+2.9 percentage points
Versus placebo.
Support for healthy vascular responsiveness
Flow-mediated dilation measures how effectively an artery expands when blood flow increases.
In published research, each 1% improvement in FMD has been associated with better cardiovascular outcomes in observational populations. A 2.9% change is considered a substantial magnitude in the FMD literature.
FMD effect size vs. lifestyle interventions
Values shown as % improvement, from published studies in similar adult populations.
Provides support for healthy endothelial function.
Arterial flexibility
PWV
1.18 m/s favorable difference
Versus placebo.
Support for healthier arterial flexibility
Carotid-femoral pulse wave velocity is a widely used measure of arterial flexibility.
In the general population, PWV tends to worsen by roughly 1 m/s per decade of life, so a 1.18 m/s favorable difference is notable. To our knowledge, this magnitude of improvement in a controlled dietary supplement study is the largest ever achieved.
PWV effect size vs. lifestyle interventions
Values shown as m/s improvement, from published studies in similar adult populations.
NOVOS Core helped support healthy arterial flexibility, which is rare for a dietary supplement.
Healthy blood pressure support
SBP
6.1 mmHg placebo-adjusted difference
Versus placebo.
Supports maintenance of healthy systolic blood pressure already within the normal range
A placebo-adjusted difference of this size is considered large and meaningful in cardiovascular biomarker research. This describes the biomarker response observed in the study, not a claim that NOVOS Core treats or prevents disease.
SBP effect size vs. lifestyle interventions
Values shown as mmHg reduction, from published studies in similar adult populations.
Beneficial effects on maintenance of healthy blood pressure already within the normal range.
Randomized, double-blind, placebo-controlled human research. Outcomes reflect physiological biomarkers rather than disease outcomes. Results should be interpreted in the context of the studied population and full protocol. Individual results may vary. Comparisons to lifestyle interventions are not head-to-head: they come from distinct, independent studies with different protocols and populations. NOVOS does not claim that NOVOS Core is superior to healthy lifestyle modifications, which remain foundational to cardiovascular health.
One formula.
Three independent vascular measures.
Randomized human evidence.
The first of its kind dietary supplement to have documented positive and simultaneous effects on endothelial function, arterial flexibility, and healthy blood pressure already within the normal range.
These results are uncommon in dietary supplement research.
Systematic literature benchmark
How unusual were the NOVOS Core cardiovascular results?
Rather than compare Core against a handful of convenient studies, NOVOS reviewed the randomized clinical literature for commonly marketed heart-health supplement ingredients.
Positive results counted. Null results counted too.
How often did published supplement trials produce effects as large and as broad as NOVOS Core?
Separate published trials. Not direct head-to-head randomization.
We started with 3,388 published records.
3,388
PubMed records identified
3,384
Records screened
147
Qualifying randomized controlled trials
142
Unique competitor studies
171
Study-marker comparisons
55 like-for-like fasted comparisons
36
Blood pressure
8
Arterial flexibility
11
Endothelial function
37
Statistically significant qualifying trial results
110
Null qualifying trial results
Null studies were not thrown away.
A supplement literature review can look much more impressive if only successful studies are shown. This benchmark retained qualifying null results as well as significant results.
- Population
- Apparently healthy adults, with the permitted inclusion rules defined by the methodology.
- Intervention
- A single supplement ingredient or its standard forms.
- Control
- Placebo or inert control.
- Outcome
- At least one of systolic blood pressure, arterial flexibility or endothelial function.
- Analysis
- Placebo-adjusted between-group effects.
- Inclusion
- Statistical significance did not determine whether a qualifying study entered the database. Both positive and null evidence was included.
- Meals shift the measurement
- Meals can temporarily influence vascular tone, blood flow and blood-pressure measurements. The NOVOS Core sustained measurements were taken fasted.
- Same measurement context. Tougher comparison.
- For the strictest like-for-like comparison, competitor results also had to be measured under fasted conditions. This produced the 55-comparison primary benchmark.
- Still a limitation
- This does not eliminate every source of cross-study variability.
Across like-for-like trials, Core set an unusually high bar.
Blood pressure
Outperformed 94%
34 of 36 fasted comparisons
Arterial flexibility
Outperformed 100%
8 of 8 fasted comparisons
Endothelial function
Outperformed 64%
7 of 11 fasted comparisons
96%
across the complete 171-comparison database
Outperforms most single-ingredient supplements on every major vascular aging marker.
Separate published trials. Not direct head-to-head randomization.
- Core exceeded a comparison when
- The competitor (1) did not demonstrate a statistically significant effect, or (2) demonstrated a statistically significant effect smaller than the Core benchmark.
- A competitor exceeded Core when
- It demonstrated a statistically significant effect larger than Core under the applicable comparison conditions.
- What this is not
- This is the benchmark methodology. It is not a direct clinical trial comparing products in the same participants.
On arterial flexibility, Core led every comparison we found.
Even when the fasting restriction was relaxed for competitors.
NOVOS Core
1.18 m/s
Magnesium
1.00 m/s
Omega-3
0.20 m/s
Beetroot / nitrate
NS
L-Arginine
NS
Garlic
NS
Orange is NOVOS Core. Green is a statistically significant competitor result. Light gray means no statistically significant demonstrated effect (NS). This wider arterial-flexibility comparison includes both fasted and non-fasted competitor trials.
12 of 12
arterial-flexibility comparisons surpassed
NOVOS Core helped support healthy arterial flexibility, which is rare for a dietary supplement.
Pressure wave travels differently through compliant arteries. Aging is associated with changes in arterial elasticity. Pulse wave velocity provides a functional measure of arterial flexibility. Lower values indicate a more favorable result.
No two people react precisely the same way to nutritional interventions. Individual results will vary, with some obtaining no benefit. Comparisons use results from separate published trials involving different populations and protocols. They are not direct head-to-head randomized comparisons.
How did Core compare with the average published result?
Healthy blood pressure
2.4x
Arterial flexibility
2.7x
Endothelial function
1.2x
Strong across all three, not just one.
These averages come from separate randomized studies involving different participants and protocols.
Omega-3 was the strongest broad comparator because qualifying omega-3 research included significant results involving all three vascular measures. Instead of averaging only successful omega-3 studies, the benchmark includes qualifying fasted trials reporting numerical results, including null results.
Blood pressure
2.1x
Arterial flexibility
5.9x
Endothelial function
1.4x
Strong across all three, not just one.
In this published-trial benchmark, the NOVOS Core effect was larger across all three measures than the average result across qualifying fasted omega-3 trials.
No two people react precisely the same way to nutritional interventions. Individual results will vary, with some obtaining no benefit. Comparisons use results from separate published trials involving different populations and protocols. They are not direct head-to-head randomized comparisons.
Effect distribution
Qualifying comparisons, plotted.
Core exceeded 34 of 36
NOVOS Core 6.1 mmHg
- Omega-3: 2.9 mmHg. Statistically significant. Omega-3
- Beetroot: 4.1 mmHg. Statistically significant. Beetroot
- Magnesium: 2 mmHg. Statistically significant. Magnesium
- Garlic: 3.2 mmHg. Statistically significant. Garlic
- Spirulina: 2.2 mmHg. Statistically significant. Spirulina
- L-Arginine: 1.4 mmHg. Statistically significant. L-Arginine
- Folate: 0.4 mmHg. No significant effect demonstrated. Folate
- L-Carnitine: 0.9 mmHg. No significant effect demonstrated. L-Carnitine
Green dots are statistically significant competitor results. Gray dots are qualifying comparisons with no significant demonstrated effect. Yellow dots mark the average across multiple studies of the same ingredient. Hover or focus a dot for detail. The dashed orange line is the NOVOS Core benchmark. Separate published trials. Not direct head-to-head randomization.
Core exceeded 8 of 8
NOVOS Core 1.18 m/s
- Magnesium: 1 m/s. Statistically significant. Magnesium
- Omega-3: 0.2 m/s. Statistically significant. Omega-3
- Beetroot: 0.1 m/s. No significant effect demonstrated. Beetroot
- L-Arginine: 0.15 m/s. No significant effect demonstrated. L-Arginine
- Garlic: 0.05 m/s. No significant effect demonstrated. Garlic
- Folate: 0.3 m/s. No significant effect demonstrated. Folate
Green dots are statistically significant competitor results. Gray dots are qualifying comparisons with no significant demonstrated effect. Yellow dots mark the average across multiple studies of the same ingredient. Hover or focus a dot for detail. The dashed orange line is the NOVOS Core benchmark. Separate published trials. Not direct head-to-head randomization.
Core exceeded 7 of 11
NOVOS Core 2.9 pp
- Omega-3: 2 pp. Statistically significant. Omega-3
- Beetroot: 3.4 pp. Statistically significant. Beetroot
- L-Arginine: 3.1 pp. Statistically significant. L-Arginine
- Folate: 3.6 pp. Statistically significant. Folate
- Magnesium: 1.1 pp. No significant effect demonstrated. Magnesium
- Garlic: 0.8 pp. No significant effect demonstrated. Garlic
Green dots are statistically significant competitor results. Gray dots are qualifying comparisons with no significant demonstrated effect. Yellow dots mark the average across multiple studies of the same ingredient. Hover or focus a dot for detail. The dashed orange line is the NOVOS Core benchmark. Separate published trials. Not direct head-to-head randomization.
Improving one marker has been achieved. All 3, to this degree, is a first.
| Supplement | Healthy blood pressure | Arterial flexibility | Endothelial function |
|---|---|---|---|
| NOVOS Core | 3 of 3 | 3 of 3 | 3 of 3 |
| Omega-3 / Fish oil | 2 of 3 | 1 of 3 | 2 of 3 |
| Beetroot / Nitrate | 2 of 3 | X | 2 of 3 |
| Magnesium | 1 of 3 | 2 of 3 | X |
| Folate | X | – | 1 of 3 |
| L-Arginine | 1 of 3 | X | 1 of 3 |
| Garlic | 1 of 3 | X | X |
| L-Carnitine | 1 of 3 | – | – |
| Spirulina | 1 of 3 | – | X |
3 of 3
Effect matched or exceeded the Core magnitude among successful trials
2 of 3
At least half of Core’s effect magnitude
1 of 3
A smaller demonstrated effect
X
Tested, but no statistically significant effect demonstrated
–
Not evaluated in the qualifying dataset
Core was the only supplement in the analysis to show a full-strength profile across all three measures.
- Search pool
- 3,388 PubMed records.
- Qualifying RCTs
- 147.
- Unique competitor studies
- 142.
- Study-marker comparisons
- 171.
- Strict like-for-like set
- 55 fasted comparisons.
- Biomarkers
- Systolic blood pressure, arterial flexibility and endothelial function.
- Analysis
- Between-group, placebo-adjusted effects.
- Null results
- Retained.
- Important limitation
- The comparison combines results from separate studies involving different populations and protocols. It is not a direct randomized head-to-head trial.
One formulation.
Three independent vascular measures.
Randomized human evidence.
Results uncommon in supplement research.
Delivers vascular benefits rarely seen with dietary supplements and nutrition.
Sets a new benchmark for what a longevity supplement can achieve in humans.
Cardiovascular health was the test system. Longevity was the design objective.
NOVOS Core was not formulated as a conventional heart supplement.
It was built as a coordinated multi-pathway formulation designed around the biology of aging.
Cardiovascular physiology was selected as the first human system to measure because it is sensitive to age-related change and can be evaluated with validated functional endpoints.
Provides nutritional support for biological systems predictive of lifespan and healthspan.
The cardiovascular trial demonstrates functional engagement of one major aging-related physiological system in humans. It does not mean cardiovascular biology is the only system Core was designed to support.
The longevity foundation
Clinically studied
NOVOS Core
The human trial measured one physiological system. Core was designed around twelve mechanisms of aging.
A formula is not simply the sum of its ingredients.
A modern longevity stack often begins by finding several individually promising compounds and assuming their effects will add together. That assumption is not always correct.
Researchers studying combinations of longevity compounds in lifespan models have found:
- synergistic combinations (8% of combinations)
- additive combinations (31% of combinations)
- neutral combinations (8% of combinations)
- combinations that performed worse than the strongest individual intervention (38% of combinations)
- combinations that negatively affected lifespan in the model (15% of combinations)
Preclinical model
Synergy should be tested, not assumed.
That is why NOVOS studies Core as a complete formulation.
Stack
- Ingredient A
- Ingredient B
- Ingredient C
- Ingredient D
- Ingredient E
Promising separately.
System
- Hallmarks
- Physiology
- Finished-formula research
Designed together. Studied together.
NOVOS Core was built as a system by carefully evaluating its bio pathways with a team of researchers, rather than just stacking together trendy ingredients.
Preclinical
Longevity research still has to ask the lifespan question.
Aged animal modelComplete Core formulationLifespan and healthspan outcomes
Statistically significant results on lifespan and healthspan in aged animal models were observed.
Animal lifespan studies can test long-duration whole-organism outcomes that cannot practically be studied across a human lifespan. They do not establish that NOVOS Core extends human lifespan.
- Study type
- Aged-animal lifespan and healthspan research using the complete Core formulation.
- Measured
- Median lifespan plus functional health measures.
- Finding
- Where currently cleared for commercial display, an 18% greater median lifespan versus control was reported.
- Does not prove
- Human lifespan extension or disease prevention.
Biological pace of aging
Can we measure how quickly someone is aging?
DunedinPACE is designed to estimate biological Pace of Aging from epigenetic patterns. In a preliminary observational NOVOS study, participants used Core plus Boost and completed biological-aging testing over time.
73%
showed a measurable reduction in Pace of Aging
Humans were studied, but without randomization or a placebo group. Findings are preliminary and cannot establish causation.
Small observational study. No placebo group. Preliminary evidence. DunedinPACE is a research-informed biological-aging biomarker, not a clinical disease outcome.
A longevity routine still has to fit real life.
NOVOS Core also provides short term benefits
Energy
Sleep
Calm focus
Mood
Skin
Cardiovascular physiology
Cellular aging
Pace of Aging research
Hallmarks
Preclinical lifespan research
Longevity matters later. The routine still has to make sense today.
Daily experience positioning reflects ingredient-level research and customer reporting. It does not mean every subjective benefit was measured in the Core randomized study.
81% of surveyed NOVOS customers reported feeling a difference within two weeks across six areas of wellbeing.
Areas surveyed: energy, sleep, cognition, mood, skin and overall wellbeing.
Self-reported customer survey. Not a randomized clinical trial. Individual results may vary.
The people behind the formulation
Built with people who study why we age.
Genomics pioneer whose laboratory studies the genetics of aging and reprogramming.
Neurobiologist studying plant compounds, cellular stress resilience and brain aging.
Biogerontologist researching the comparative biology and genetics of lifespan.
Longevity researcher focused on multi-pathway formulation design and evaluation.
Science that clinicians enthusiastically recommend.
2,000+
verified MDs & clinicians recommend NOVOS
Clinician status is confirmed through the NOVOS clinician-verification framework.
Available at
Mayo Clinic Store · Bumrungrad International Hospital · Remedy Place · Erewhon · Select Four Seasons & Equinox
Retail availability is not an institutional medical endorsement. Individual physician quotes should use exact approved wording with name and affiliation.
Supplements are only one part of longevity.
NOVOS Life turns broader longevity science into personalized daily recommendations spanning products, nutrition, exercise, sleep and lifestyle.
Learn
NOVOS science and education
Support
Core, Boost, Vital, Bar
Measure
NOVOS Age
Personalize
NOVOS Life
Built for more than selling supplements.
NOVOS is a Public Benefit Corporation with a stated mission centered on longevity science, healthspan and accessible longevity education.
Part of the professional longevity ecosystem.
NOVOS participates in the Longevity Biotechnology Association and the Healthy Longevity Medicine Society. This is an organizational credibility signal, not product efficacy evidence.
Different supplements solve different problems.
Nutrient sufficiency
Multivitamin
Useful. Not usually designed as a multi-pathway aging formulation.
Convenient plant nutrition
Greens powder
Useful for nutrition. Not automatically a longevity formulation.
Oxidative-stress biology
Antioxidant blend
One piece of a larger aging system.
NAD+ and cellular energy
NAD+ supplement
An important pathway. Still focused.
One targeted pathway
Single longevity ingredient
Fisetin, AKG, glycine or polyphenols may have valuable evidence. Still one ingredient.
Multi-pathway longevity foundation
NOVOS Core
Designed around the Hallmarks. Complete formulation studied.
What should you compare before buying?
| Standard | NOVOS Core | Single NAD+ supplement | Multivitamin | Greens powder | Single longevity ingredient |
|---|---|---|---|---|---|
| Designed around aging biology | Primary | One pathway | General health, not aging biology | n/a | One pathway |
| Multi-longevity pathway design | Yes, 12 | Limited to 1 | No | No | Limited to 1 |
| Complete formulation studied | Yes | Varies | Rare | Rare | Ingredient itself |
| Finished-product randomized human research | Yes | Varies | Rare | Rare | Ingredient-level |
| Full formula animal lifespan research | Yes | No | No | No | No |
| Human biological aging research | Preliminary Core + Boost | Rare | Rare | Rare | Rare |
| Full ingredient disclosure | Yes | Yes | Yes | No | Yes |
| Longevity scientist development | Yes | Rare | Rare | No | Rare |
Brands within each category vary substantially. The table describes common category positioning and is not a claim about every product.
What we know. What we do not.
What we know
- Core’s complete formulation has been evaluated in randomized human research.
- The study showed beneficial effects over placebo across multiple independent functional measures associated with healthspan and lifespan.
- Core extended aged animal lifespan.
- Core plus Boost have preliminary research showing reduced epigenetic pace of aging.
- Core has in vitro research showing improvements in DNA protection, cellular senescence, oxytosis/ferroptosis, and cellular inflammation.
- The complete formula is patent-pending, and 81% of users report subjective benefits after two weeks of use.
What we do not know yet
- Whether preliminary biological-age findings will replicate in larger controlled studies.
- Whether the aged animal lifespan extension translates to humans.
- Whether preliminary biological-age findings will replicate in larger placebo-controlled studies.
- The magnitude of any long term human lifespan and healthspan effect.
- If the improvements in skin firmness will replicate in larger placebo-controlled studies.
- Which other organ systems the NOVOS Core formula may impact (e.g., brain, liver, kidneys, etc.).
Good longevity science shows the limits too.
- Study type
- Randomized, double-blind, placebo-controlled human study.
- Who was studied
- Adults aged 40 and over across six months.
- Measured
- Endothelial function, arterial flexibility and healthy blood-pressure support.
- Finding
- Significant beneficial effects over placebo on multiple functional vascular measures.
- Does not prove
- Prevention or treatment of cardiovascular disease or human lifespan extension.
The best supplement cannot rescue the rest of your lifestyle.
Longevity still depends heavily on:
Exercise
Nutrition
Sleep
Metabolic health
Prevention
Stress management
Social connection
NOVOS products are designed to complement those fundamentals.
Longevity should be more than a claim.
Research should go beyond individual ingredients.
A formula should be studied as the complete formula.
Human studies should measure actual function.
Most companies market supplements.
NOVOS runs a longevity research program.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.